WuXi Biologics breaks ground on CRDMO Center in Singapore
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Oscotec has successfully completed phase 2 study in patients with chronic ITP last year
This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India
Pharma Solutions operates 10 research and development and/or production sites globally
The pilot plant is focused on scaling up beverage production and will support applications
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
New institute brings together Evonik’s most advanced biotech platform and a global network of evaluation labs
Subscribe To Our Newsletter & Stay Updated